<span item_type="fundamental" item_id="5f39f2097e3bc5162d55be7adb5a7aa7" counter_id="ST/US/BLCO" env="prod"></span><span item_type="announcement" item_id="642801140845451777" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 1.244 B, beating the estimate of USD 1.216 B.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.2, missing the estimate of USD -0.1475.</p><p>EBIT: As of FY2026 Q1, the actual value is USD 126 M.</p><p></p><h4>Total Revenue</h4><p>Bausch + Lomb Corporation reported total revenue of $1.244 billion for the first quarter of 2026, an increase of $107 million, or 9%, compared to $1.137 billion in the first quarter of 2025. On a constant currency basis, revenue grew approximately 6% compared to the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p><h4>Segment Revenue</h4><ul><li><strong>Vision Care</strong>: Revenue was $711 million for the first quarter of 2026, up $55 million or 8% from $656 million in the first quarter of 2025. Excluding foreign exchange impacts, segment revenue increased by approximately 5% on a constant currency basis, driven by sales from over-the-counter dry eye products, LUMIFY®, and SiHy Daily lenses <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</li><li><strong>Surgical</strong>: Revenue reached $228 million in the first quarter of 2026, an increase of $14 million or 7% from $214 million in the first quarter of 2025. On a constant currency basis, segment revenue increased by approximately 1%, primarily due to growth in premium IOLs and consumables <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</li><li><strong>Pharmaceuticals</strong>: Revenue was $305 million for the first quarter of 2026, marking an increase of $38 million or 14% from $267 million in the first quarter of 2025. On a constant currency basis, segment revenue grew by approximately 12%, largely driven by increased sales of MIEBO® (+33%) and XIIDRA® (+30%), and growth in International Pharmaceuticals <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</li></ul><h4>Operating Income</h4><p>Operating income for the first quarter of 2026 was $33 million, a favorable change of $116 million compared to an operating loss of - $83 million in the first quarter of 2025. This change was attributed to revenue performance and operating efficiencies <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p><h4>Net Loss Attributable to Bausch + Lomb Corporation</h4><p>Net loss attributable to Bausch + Lomb Corporation was - $71 million for the first quarter of 2026, a favorable change of $141 million from - $212 million in the first quarter of 2025. This improvement was primarily due to increased operating results and a favorable change in the provision for income taxes <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p><h4>Adjusted Net Income (non-GAAP)</h4><p>Adjusted net income attributable to Bausch + Lomb Corporation (non-GAAP) was $19 million in the first quarter of 2026, a favorable change of $73 million from an adjusted net loss of - $54 million in the first quarter of 2025 <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p><h4>Cash Flow from Operations</h4><p>Cash flow from operations for the first quarter of 2026 was $32 million, a favorable change of $57 million compared to cash flow used in operations of - $25 million in the first quarter of 2025. The positive impact was linked to operating results <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p><h4>Adjusted EBITDA (non-GAAP)</h4><p>Adjusted EBITDA (non-GAAP) was $189 million for the first quarter of 2026, an increase of $91 million from $98 million in the first quarter of 2025. Adjusted EBITDA excluding Acquired IPR&amp;D (non-GAAP) was $200 million for the first quarter of 2026, an increase of $74 million from $126 million in the first quarter of 2025. These increases were driven by revenue performance and operating efficiencies <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p><h4>Balance Sheet Highlights</h4><p>As of March 31, 2026, Bausch + Lomb Corporation held $279 million in cash, cash equivalents, and restricted cash <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p><h4>2026 Financial Outlook</h4><p>Bausch + Lomb Corporation raised its full-year 2026 guidance for both revenue and Adjusted EBITDA Excluding Acquired IPR&amp;D (non-GAAP) <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>. The company now expects full-year revenue to be between $5.420 billion and $5.520 billion, with constant currency growth projected at 5.3% to 7.2% <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>. Full-year Adjusted EBITDA Excluding Acquired IPR&amp;D (non-GAAP) is anticipated to range from $1.010 billion to $1.060 billion <span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860742/000186074226000060/ex991q1-2026.htm"></span>.</p>

Bausch + Lomb | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 1.244 B